Pfizer Oncology Sponsored Abstracts
2024 American Society of Clinical Oncology (ASCO) Annual Meeting
The majority of Annual Meeting abstracts will be released at 5:00 PM EDT on Thursday, May 23, 2024. Late-Breaking Abstracts (LBAs) will be released at 7:00 AM (CDT) on the day of scientific presentation at the meeting.

Key:
Oral Presentation
Rapid Oral Presentation

Breast Cancer			
Pfizer Asset	**Abstract Number / Study / Abstract Title**	**Type**	**Date / Time**
Atirmociclib (PF-07220060; CDK4i)	**3108** First-in-human phase 1/2a study of the first-in-class, next generation CDK4-selective inhibitor PF-07220060 + endocrine therapy (ET): Updated safety data in patients with HR+/HER2− mBC	Poster Presentation	June 1 9:00 AM-12:00 PM CDT
Atirmociclib (PF-07220060; CDK4i)	**TPS1129** International phase 3 clinical trial evaluating PF-07220060 plus fulvestrant in patients with HR+/HER2− advanced/metastatic breast cancer with progression after a prior CDK4/6 inhibitor	Poster Presentation	June 2 9:00 AM-12:00 PM CDT
Enfortumab vedotin	**1005** Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202	Oral Presentation	June 1 3:00-6:00 PM CDT
Palbociclib	**1055** Impact of prior anticancer treatments on palbociclib (PAL) clinical outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC) in real-world settings	Poster Presentation	June 2 9:00 AM-12:00 PM CDT

Palbociclib	**1111** Overall survival with palbociclib (PAL) plus an aromatase inhibitor (AI) versus AI alone in older patients (pts) with de novo, HR+/HER2− metastatic breast cancer: A SEER-Medicare analysis	Poster Presentation	June 2 9:00 AM-12:00 PM CDT
PF-07248144 (KAT6)	**3006** A phase 1 dose expansion study of a first-in-class KAT6 inhibitor— (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer	Oral Presentation	June 1 3:00-6:00 PM CDT
Tucatinib	**1105** Tucatinib and trastuzumab for previously treated HER2-mutated metastatic breast cancer (SGNTUC-019): A phase 2 basket study	Poster Presentation	June 2 9:00 AM-12:00 PM CDT
Vepdegestrant	**TPS1131** TACTIVE-K: phase 1b/2 study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK) 4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer	Poster Presentation	June 2 9:00 AM-12:00 PM CDT
Genitourinary Cancer			
Pfizer Asset	**Abstract Number / Study / Abstract Title**	**Type**	**Date / Time**
Disitamab vedotin	**TPS4616** Phase 3 study of disitamab vedotin with pembrolizumab vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001)	Poster Presentation	June 2 9:00 AM-12:00 PM CDT

Enfortumab vedotin	**4502** Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)	Oral Presentation	June 3 8:00-11:00 AM CDT
Enfortumab vedotin	**4503** Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer	Oral Presentation	June 3 8:00-11:00 AM CDT
Enfortumab vedotin	**4562** Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of cisplatin (cis)-eligible population from EV-302/KEYNOTE-A39	Poster Presentation	June 2 9:00 AM-12:00 PM CDT
Enfortumab vedotin	**4563** Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39	Poster Presentation	June 2 9:00 AM-12:00 PM CDT
Enfortumab vedotin	**4564** Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC): 2-year event-free survival and safety data for Cohort H	Poster Presentation	June 2 9:00 AM-12:00 PM CDT
Enfortumab vedotin	**e23287** Real-world first-line treatment patterns and outcomes in patients with locally advanced or metastatic urothelial carcinoma in the United States	Publication Only	N/A

Enfortumab vedotin	**e16547** Systematic literature review and network meta-analysis of first-line therapies for locally advanced/metastatic urothelial carcinoma	Publication Only	N/A
Enzalutamide	**5005** EMBARK post-hoc analysis of impact of treatment suspension (TxS) on health-related quality of life (HRQoL)	Oral Presentation	June 1 3:00-6:00 PM CDT
Enzalutamide	**5084** EMBARK post-hoc analysis of sexual activity (SA) patient-reported outcomes (PROs) in patients (pts) who were sexually active or interested in sex at baseline (BL)	Poster Presentation	June 2 9:00 AM-12:00 PM CDT
Enzalutamide	**5087** Physicians use of first-line treatment intensification in metastatic castration-sensitive prostate cancer (mCSPC): A discrete choice experiment	Poster Presentation	June 2 9:00 AM-12:00 PM CDT
Enzalutamide	**e17071** Characteristics and treatment (Tx) patterns (TxP) of high-risk biochemically recurrent (HR-BCR) non-metastatic castration-sensitive prostate cancer in the real-world by race, age, and prostate-specific antigen (PSA) doubling time (PSADT)	Publication Only	N/A
Enzalutamide	**224** Barriers and facilitators to first-line treatment intensification in metastatic castration-sensitive prostate cancer (mCSPC): The IMPLEMENT study	Publication Only	N/A

Mevrometostat	**5061** Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC)	Poster Presentation	June 2 9:00 AM-12:00 PM CDT
Relugolix	**e17072** Interim analysis of clinical data and reasons for initiating relugolix on a cohort of US patients: The OPTYX study	Publication Only	N/A
Relugolix	**e17110** Evaluation of persistence and adherence for oral and injectable androgen deprivation therapies (ADT) in United States (US) patients with prostate cancer (PC)	Publication Only	N/A
Talazoparib	**5020** Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)	Poster Presentation	June 2 9:00 AM-12:00 PM CDT
Talazoparib	**5021** Discovery of a novel non-negative matrix factorization (NMF) - based homologous recombination deficiency (HRD) score and subsequent exploration in TALAPRO-2 (TP-2), a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)	Poster Presentation	June 2 9:00 AM-12:00 PM CDT

Talazoparib	**5023** Exploration of circulating tumor cell (CTC) conversion and CTC0 as prognostic biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)	Poster Presentation	June 2 9:00 AM-12:00 PM CDT
Talazoparib	**5063** Matching-adjusted indirect comparisons (MAICs) of talazoparib plus enzalutamide (TALA+ENZA) versus olaparib plus abiraterone and prednisone/prednisolone (OLAP+AAP) for first-line (1L) therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair mutations (HRRm)/BRCAm	Poster Presentation	June 2 9:00 AM-12:00 PM CDT
Hematology-Oncology			
Pfizer Asset	**Abstract Number / Study / Abstract Title**	**Type**	**Date / Time**
Brentuximab vedotin	**LBA7005 – ECHELON-3** Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study	Oral Presentation	June 1 3:00-6:00 PM CDT
Brentuximab vedotin	**7053** Seven-year overall survival analysis from ECHELON-1 study of A+AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma	Poster Presentation	June 3 9:00 AM-12:00 PM CDT
Brentuximab vedotin	**7069** Frontline brentuximab vedotin and CHP (A+CHP) in patients (pts) with peripheral T-cell lymphoma with less than 10% CD30 expression: results from the phase 2 SGN35-032 study	Poster Presentation	June 3 9:00 AM-12:00 PM CDT

Elranatamab	**7522** Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9	Poster Presentation	June 3 9:00 AM-12:00 PM CDT
Elranatamab	**TPS7576** Evaluation of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma and prior anti-CD38–directed therapy: MagnetisMM-32	Poster Presentation	June 3 9:00 AM-12:00 PM CDT
Elranatamab	**7546** Characterization of the BCMA epitope bound by BCMA-CD3 T cell engager elranatamab	Poster Presentation	June 3 9:00 AM-12:00 PM CDT
Elranatamab	**TPS7577** MagnetisMM-30: a phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM)	Poster Presentation	June 3 9:00 AM-12:00 PM CDT
Gemtuzumab	**e18504** Safety outcomes in adult patients with AML who achieved their first complete remission with GO prior to HSCT	Publication Only	N/A
Gemtuzumab	**6516** Safety outcomes in patients with acute myeloid leukemia receiving gemtuzumab ozogamicin and proceeding to hematopoietic stem cell transplantation	Rapid Oral Presentation	June 1 8:00 AM-9:30 AM CDT
Thoracic Cancer			
Pfizer Asset	**Abstract Number / Study / Abstract Title**	**Type**	**Date / Time**
Enfortumab vedotin	**4046** Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202	Poster Presentation	June 1 1:30 PM-4:30 PM CDT

Enfortumab vedotin	**TPS6116** Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial	Poster Presentation	June 2 9:00 AM-12:00 PM CDT
Enfortumab vedotin	**8585** Enfortumab vedotin (EV) in non-squamous and squamous non–small cell lung cancer (NSCLC) cohorts of EV-202	Poster Presentation	June 3 1:30-4:30 PM CDT
Lorlatinib	**LBA8503 – CROWN** Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study	Oral Presentation	May 31 2:45-5:45 PM CDT
Sigvotatug vedotin (SGN-B6A)	**8521** Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001)	Rapid Oral Presentation	June 1 4:30-6:00 PM CDT
Tisotumab vedotin	**6012** Tisotumab vedotin in head and neck squamous cell carcinoma: Updated analysis from innovaTV 207 Part C	Rapid Oral Presentation	June 3 8:00-9:30 AM CDT
Gynecological Cancer			
Pfizer Asset	**Abstract Number / Study / Abstract Title**	**Type**	**Date / Time**
Maplirpacept	**e17546** A phase I/II study of maplirpacept in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer (OC): Phase 1 results	Publication Only	N/A
Tisotumab vedotin	**5531** Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301	Poster Presentation	June 3 9:00 AM-12:00 PM CDT

Gastrointestinal			
Pfizer Asset	**Abstract Number / Study / Abstract Title**	**Type**	**Date / Time**
Encorafenib	**e23146** Adherence and persistence of encorafenib in combination with cetuximab among BRAF metastatic CRC in the United States (US) based on two claims databases	Publication Only	N/A
Tucatinib	**3509** Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER)	Rapid Oral Presentation	June 3 1:15-2:45 PM CDT
Pan-Tumor			
Pfizer Asset	**Abstract Number / Study / Abstract Title**	**Type**	**Date / Time**
Brentuximab vedotin	**2617** Ph 2 trial of brentuximab vedotin (BV) with pembrolizumab (pembro) in patients with previously treated metastatic non-small cell lung cancer (NSCLC) or cutaneous melanoma (SGN35-033): Overall survival	Poster Presentation	June 1 9:00 AM-12:00 PM CDT
PF-07799544 (ARRY-134)	**TPS3180** A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799544 (ARRY-134) as a single agent and in combination with PF-07799933 BRAF dimer inhibitor, in participants 16 years and older with advanced solid tumors	Poster Presentation	June 1 9:00 AM-12:00 PM CDT
SGNCEAC5C-001	**TPS3160** An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001)	Poster Presentation	June 1 9:00 AM-12:00 PM CDT

N/A	**11141** Estimating adult cancer cachexia prevalence and impact on survival in the US: Real-world data analysis	Poster Presentation	June 3 9:00 AM-12:00 PM CDT
Biosimilars			
Pfizer Asset	**Abstract Number / Study / Abstract Title**	**Type**	**Date / Time**
Biosimilars	**e23052** Cost-Efficiency Modeling of Conversion to Biosimilar Bevacizumab-bvzr in Metastatic Colorectal Cancer in Medicare	Publication Only	N/A